Список клинических и доклинических исследований, доказывающих эффективность ингредиентов HairWake при борьбе с выпадением волос, стимуляцией роста волос, укреплением и усилением волосяного фолликула и волоса.

Список клинических и доклинических исследований, доказывающих эффективность ингредиентов HairWake при борьбе с выпадением волос, стимуляцией роста волос, укреплением и усилением волосяного фолликула и волоса.

1. REGULATION OF CELL VOLUME IN HEALTH AND DISEASE
MICHAEL L. MCMANUS, M.D., KEVIN B. CHURCHWELL, M.D., AND K EVIN S TRANGE , P H .D.
The New England Journal of Medicine Nov 9.1995 p. 1260

2. Expression of myo-inositol oxygenase in tissues susceptible to diabetic complications.
Arner RJ, Prabhu KS, Krishnan V, Johnson MC, Reddy CC.
Department of Veterinary and Biomedical Sciences, The Center for Molecular Toxicology and Carcinogenesis, 115 Henning Building, The Pennsylvania State University, University Park, USA.

3. Effects of dietary myo-inositol, D-chiro-inositol and L-chiro-inositol on hepatic lipids with reference to the hepatic myo-inositol status in rats fed on 1,1,1-trichloro-2,2-bis (p-chlorophenyl) ethane.
Okazaki Y, Setoguchi T, Katayama T.
Department of Human Life Sciences Education, Graduate School of Education, Hiroshima University, Higashi-Hiroshima, Japan.

4. The role of inositol 1,4,5-trisphosphate receptors in the regulation of bile secretion in health and disease.
Pusl T, Nathanson MH.
Department of Medicine II, Klinikum of the University of Munich-Grosshadern, Munich, Germany.

5. Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis.
Lee HJ, Lee SA, Choi H.
Nutrition Science Lab., Department of Food and Nutrition, Seoul National University, Seoul 151-742, Korea.

6. STUDIES ON MYOINOSITOL : (VI) ON THE GROWTH PROMOTING AND LIPOTROPIC EFFECT OF FATTY ACID ESTERS OF MYOINOSITOL
KOTAKI Akira, NATSUME Kazuko, SAKURAI Torao, YAMAMOTO Yoshiko, YAGI Kunio
Institute of Biochemistry, Faculty of Medicine, University of Nagoya, Japan.

7. Expression of myo-inositol oxygenase in tissues susceptible to diabetic complications.
Arner RJ, Prabhu KS, Krishnan V, Johnson MC, Reddy CC.
Department of Veterinary and Biomedical Sciences, The Center for Molecular Toxicology and Carcinogenesis, 115 Henning Building, The Pennsylvania State University, University Park, PA 16802, USA.

8. Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose. In vitro model of myo-inositol depletion hypothesis of diabetic complications.
Del Monte MA, Rabbani R, Diaz TC, Lattimer SA, Nakamura J, Brennan MC, Greene DA.
Department of Ophthalmology, University of Michigan, USA.

9. [Abnormal inositol phospholipid metabolism as a main factor causing pericyte drop-out in diabetic retinopathy] [Article in Chinese] Li WY.

10. Peripheral neuropathy: pathogenic mechanisms and alternative therapies.
Head KA.
Thorne Research, Inc., PO Box 25, Dover, ID 83825, USA.

11. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study.
Agostini R, Rossi F, Pajalich R.
First Institute of Obstetrics and Gynecology, University La Sapienza, Rome, Italy.

12. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance.
Sundkvist G, Dahlin LB, Nilsson H, Eriksson KF, Lindgarde F, Rosen I, Lattimer SA, Sima AA, Sullivan K, Greene DA.
Department of Endocrinology, University of Lund, Malmo University Hospital, Sweden.

13. Supplemental myo-inositol prevents L-fucose-induced diabetic neuropathy.
Sima AA, Dunlap JA, Davidson EP, Wiese TJ, Lightle RL, Greene DA, Yorek MA.
Department of Pathology, Wayne State University, Detroit, Michigan, USA.

14. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls.
Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J.
Insmed Incorporated, 4851 Lake Brooke Dr., Glen Allen, USA.

15. Inositol for respiratory distress syndrome in preterm infants.
Howlett A, Ohlsson A.
Paediatrics (Division of Neonatal Paediatrics), Izaak Walton Killam-Grace Health Centre, 5850/5980 University Avenue, Halifax, Nova Scotia, Canada

16. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study.
Friedman CA, McVey J, Borne MJ, James M, May WL, Temple DM, Robbins KK, Miller CJ, Rawson JE.
Division of Newborn Medicine, Methodist Medical Center, Jackson, Miss, USA.

17. Complementary medicines in pediatric bipolar disorder.
Bogarapu S, Bishop JR, Krueger CD, Pavuluri MN.
Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, College of Medicine, Chicago, USA.

18. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex.
Moore CM, Breeze JL, Gruber SA, Babb SM, Frederick BB, Villafuerte RA, Stoll AL, Hennen J, Yurgelun-Todd DA, Cohen BM, Renshaw PF.
Brain Imaging Center, McLean Hospital, Belmont, USA.

19. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
Silverstone PH, McGrath BM, Kim H.
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.

20. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder.
Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M, McCracken J.
Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California, Los Angeles, USA.

21. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents.
Davanzo P, Yue K, Thomas MA, Belin T, Mintz J, Venkatraman TN, Santoro E, Barnett S, McCracken J.
Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, USA.

22. STEP-BD and bipolar depression: what have we learned?
Thase ME.
University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, USA.

23. Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain.
Tyeryar KR, Vongtau HO, Undieh AS.
Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, USA.

24. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS.
Massachusetts General Hospital Bipolar Clinic and Research Program, Suite 580, 50 Staniford Street, Boston, USA.

25. Decreased prefrontal Myo-inositol in major depressive disorder.
Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS.
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.

26. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
IVF Unit, Gynaecological-Obstetric Department, IRCCS San Raffaele Hospital, Vita-Salute University, Milan, Italy.

27. Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis.
Lee HJ, Lee SA, Choi H.
Nutrition Science Lab., Department of Food and Nutrition, Seoul National University, Seoul, Korea.

28. Apoptotic effects of inositol hexaphosphate on biomarker Itpr3 in induced colon rat carcinogenesis.
Guido M, Fagundes DJ, Ynouye CM, Pontes ER, Takita LC, Amaral EG, Teruya R, Paes MC, Brasileiro JL, Aydos RD.
Program in Surgery and Experimentation, Department of Surgery, UNIFESP-SP, Sao Paulo, Brazil.

29. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L.
IVF unit, Gynecologic-Obstetric Department, Istituto di Ricovera e Cura a Carattere Scientifico, San Raffaele Hospital, Vita-Salute University, Milan, Italy.

30. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.
Gerli S, Papaleo E, Ferrari A, Di Renzo GC.
Department of Obstetrics and Gynecology, Monteluce Hospital, University of Perugia, Italy.

31. Protection against cancer by dietary IP6 and inositol.
Vucenik I, Shamsuddin AM.
Department of Pathology, University of Maryland School of Medicine, USA.

32. A phase I study of myo-inositol for lung cancer chemoprevention.
Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E.
Department of Respiratory Medicine, British Columbia Cancer Agency, British Columbia, Canada.

33. [Anti-inflammatory action of myoinositol in renal insufficiency]
[Article in Polish]
Rysz J, Bartnicki P, Blaszczak R, Kujawski K, Cialkowska-Rysz A, Olszewski R, Markuszewski L.
Uniwersytet Medyczny w Lodzi, Uniwersytecki Szpital Kliniczny Nr 2. Poland.

34. Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma.
Rizvi I, Riggs DR, Jackson BJ, Ng A, Cunningham C, McFadden DW.
Department of Surgery, Robert C. Byrd Health Science Center, West Virginia University, Morgantown, West Virginia, USA.

35. Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer.
Somasundar P, Riggs DR, Jackson BJ, Cunningham C, Vona-Davis L, McFadden DW.
Louis A. Johnson VA Medical Center, Clarksburg, West Virginia; Department of Surgery, West Virginia University, Morgantown, West Virginia, USA.

36. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM.
Department of Obstetrics and Gynecology, University of Modena and Reggio Emilia, Italy.

37. Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis.
Lee HJ, Lee SA, Choi H.
Nutrition Science Lab., Department of Food and Nutrition, Seoul National University, Seoul, Korea.

38. Смирнов М.И "Витамины" монография, 1974

39. Лукьянова Е.М. "Витамины в педиатрии" монография, 1984

40. Controlled trials of inositol in psychiatry.
Levine J.
Eur Neuropsychopharmacol. 1997 May;7(2):147-55.

41. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.
Palatnik A, Frolov K, Fux M, Benjamin J.
J Clin Psychopharmacol. 2001 Jun;21(3):335-9.

42. Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression.
Maes M, Mihaylova I, Leunis JC.
MCare4U Outpatient Clinics, Belgium.

43. Effect of inositol on bulimia nervosa and binge eating.
Gelber D, Levine J, Belmaker RH.
Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel.

44. Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain.
Tyeryar KR, Vongtau HO, Undieh AS.
Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, USA.

45. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Larner J.
Department of Pharmacology, University of Virginia School of Medicine, USA.

46. Induction of embryonic dysmorphogenesis by high glucose concentration, disturbed inositol metabolism, and inhibited protein kinase C activity.
Wentzel P, Wentzel CR, Gäreskog MB, Eriksson UJ.
Department of Medical Cell Biology, Uppsala University, Biomedical Center, Uppsala, Sweden.

47. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide.
Nascimento NR, Lessa LM, Kerntopf MR, Sousa CM, Alves RS, Queiroz MG, Price J, Heimark DB, Larner J, Du X, Brownlee M, Gow A, Davis C, Fonteles MC.
College of Veterinary Medicine, State University of Ceará, Fortaleza, Ceará, Brazil.

48. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes.
Chiu TT, Rogers MS, Briton-Jones C, Haines C.
Department of Obstetrics & Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.

49. Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells.
Deliliers GL, Servida F, Fracchiolla NS, Ricci C, Borsotti C, Colombo G, Soligo D.
Bone Marrow Transplantation Unit, I.R.C.C.S., Ospedale Maggiore and University of Milan, Italy.

50. The Role of Vitamins and Minerals in Hair Loss: A Review. Hind M. Almohanna,corresponding author1 Azhar A. Ahmed,2 John P. Tsatalis,3 and Antonella Tosti. Dermatol Ther (Heidelb). 2019 Mar; 9(1): 51–70.

51. 51. Gropper SS, Smith J, Grodd JL. The water-soluble vitamins. In: Gropper SS, Smith JL, Grodd JL, editors. Advanced nutrition and human metabolism, 4th edn. Belmont: Thomson Wadsworth; 2004: 260–75.
52. Fleming JD, Martin B, Card DJ, Mellerio JE. Pain, purpura and curly hairs. Clin Exp Dermatol. 2013;38(8):940–942.
53. Kechichian E, Ezzedine K. Vitamin D and the skin: an update for dermatologists. Am J Clin Dermatol. 2018;19(2):223–235.
54. D’Aurizio F, Villalta D, Metus P, Doretto P, Tozzoli R. Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases? Autoimmun Rev. 2015;14(5):363–369.
55. Thompson JM, Mirza MA, Park MK, Qureshi AA, Cho E. The role of micronutrients in alopecia areata: a review. Am J Clin Dermatol. 2017;18(5):663–679. [PMC free article]
56. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012;12(2):127–136.
57. Zhang X, Wang W, Li Y, Wang H, Liu R, Zhu L. Serum 25-hydroxyvitamin D status in chinese children with vitiligo: a case-control study. Clin Pediatr (Phila). 2018;57(7):802–805.
58. Djeraba Z, Benlabidi F, Djaballah-Ider FZ, Medjeber O, Arroul-Lammali A, Belguendouz H, et al. Vitamin D status in Algerian Behcet’s disease patients: an immunomodulatory effect on NO pathway. Immunopharmacol Immunotoxicol. 2017;39(4):243–250.
59. Wang LM, Zheng ZH, Li TF, et al. 25-hydroxyvitamin D is associated with metabolic syndrome among premenopausal women with systemic lupus erythematosus in China. Lupus. 2017;26(4):403–409.
60. Vasile M, Corinaldesi C, Antinozzi C, Crescioli C. Vitamin D in autoimmune rheumatic diseases: a view inside gender differences. Pharmacol Res. 2017;117:228–241.
61. Reichrath J, Schilli M, Kerber A, Bahmer FA, Czarnetzki BM, Paus R. Hair follicle expression of 1,25-dihydroxyvitamin D3 receptors during the murine hair cycle. Br J Dermatol. 1994;131(4):477–482.
62. Takeda E, Kuroda Y, Saijo T, et al. 1 alpha-hydroxyvitamin D3 treatment of three patients with 1,25-dihydroxyvitamin D-receptor-defect rickets and alopecia. Pediatrics. 1987;80(1):97–101.
63. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev. 1999;20(2):156–188.
64. Vupperla D, Lunge SB, Elaprolu P. Vitamin D-dependent rickets Type II with alopecia: a rare case report. Indian J Dermatol. 2018;63(2):176–179. [PMC free article]
65. Forghani N, Lum C, Krishnan S, et al. Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene. J Pediatr Endocrinol Metab. 2010;23(8):843–850.
66. Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol. 2014;170(6):1299–1304.
67. Mahamid M, Abu-Elhija O, Samamra M, Mahamid A, Nseir W. Association between vitamin D levels and alopecia areata. Isr Med Assoc J. 2014;16(6):367–370.
68. Lee S, Kim BJ, Lee CH, Lee WS. Increased prevalence of vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(7):1214–1221.
69. Thompson JM, Li T, Park MK, Qureshi AA, Cho E. Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. Arch Dermatol Res. 2016;308(9):671–676.
70. Gade VKV, Mony A, Munisamy M, Chandrashekar L, Rajappa M. An investigation of vitamin D status in alopecia areata. Clin Exp Med. 2018;18(4):577–84. [PubMed]
71. Daroach M, Narang T, Saikia UN, Sachdeva N, Sendhil Kumaran M. Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm. Int J Dermatol. 2018;57(2):217–222.
72. Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol. 2013;26(2):101–107.
73. Banihashemi M, Nahidi Y, Meibodi NT, Jarahi L, Dolatkhah M. Serum vitamin D3 level in patients with female pattern hair loss. Int J Trichol. 2016;8(3):116–120. [PMC free article]
74. Moneib HFG, Ouda A. Possible association of female-pattern hair loss with alteration in serum 25-hydroxyvitamin D levels. Egypt J Dermatol Venerol. 2014;34:15–20. [Google Scholar]
75. Nayak K, Garg A, Mithra P, Manjrekar P. Serum vitamin D3 levels and diffuse hair fall among the student population in South India: a Case-Control Study. Int J Trichol. 2016;8(4):160–164. [PMC free article]
76. Karadag ASEDT, Tutal E, Akin KO. The role of anemia and vitamin D levels in acute and chronic telogen effluvium. Turk J Med Sci. 2011;41:827–833. [Google Scholar]
77. Gerkowicz A, Chyl-Surdacka K, Krasowska D, Chodorowska G. The role of vitamin D in non-scarring alopecia. Int J Mol Sci. 2017 doi: 10.3390/ijms18122653. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
78. Knight JA. Review: free radicals, antioxidants, and the immune system. Ann Clin Lab Sci. 2000;30(2):145–158.
79. Prie BE, Voiculescu VM, Ionescu-Bozdog OB, et al. Oxidative stress and alopecia areata. J Med Life. 2015;8(Spec Issue):43–46. [PMC free article]
80. Naziroglu M, Kokcam I. Antioxidants and lipid peroxidation status in the blood of patients with alopecia. Cell Biochem Funct. 2000;18(3):169–173.
81. Ramadan R, Tawdy A, Abdel Hay R, Rashed L, Tawfik D. The antioxidant role of paraoxonase 1 and vitamin E in three autoimmune diseases. Skin Pharmacol Physiol. 2013;26(1):2–7.
82. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54(5):824–844.
83. Shrivastava SB. Diffuse hair loss in an adult female: approach to diagnosis and management. Indian J Dermatol Venereol Leprol. 2009;75(1):20–27.
84. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973;26(10):770–772. [PMC free article]
85. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002;27(5):396–404.
86. Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol. 2002;147(5):982–984.
87. Coenen JL, van Dieijen-Visser MP, van Pelt J, et al. Measurements of serum ferritin used to predict concentrations of iron in bone marrow in anemia of chronic disease. Clin Chem. 1991;37(4):560–563.
88. Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992;36(4):421–427.
89. Milman N, Kirchhoff M. Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol. 1992;64(1):22–27.
90. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol. 1993;85(4):787–798.
91. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052–1057.
92. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44(1):45–51.
93. St Pierre SA, Vercellotti GM, Donovan JC, Hordinsky MK. Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle. J Am Acad Dermatol. 2010;63(6):1070–1076.
94. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003;121(5):985–988.
95. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):389–395.
96. Rushton DH, Barth JH. What is the evidence for gender differences in ferritin and haemoglobin? Crit Rev Oncol Hematol. 2010;73(1):1–9.
97. Rushton DH, Dover R, Sainsbury AW, Norris MJ, Gilkes JJ, Ramsay ID. Why should women have lower reference limits for haemoglobin and ferritin concentrations than men? BMJ. 2001;322(7298):1355–1357. [PMC free article]
98. Hard S. Non-anemic iron deficiency as an etiologic factor in diffuse loss of hair of the scalp in women. Acta Derm Venereol. 1963;43:562–9.
99. Rushton DH, Ramsay ID, James KC, Norris MJ, Gilkes JJ. Biochemical and trichological characterization of diffuse alopecia in women. Br J Dermatol. 1990;123(2):187–197.
100. Rushton DH, Norris MJ, Dover R, Busuttil N. Causes of hair loss and the developments in hair rejuvenation. Int J Cosmet Sci. 2002;24(1):17–23.
101. White MI, Currie J, Williams MP. A study of the tissue iron status of patients with alopecia areata. Br J Dermatol. 1994;130(2):261–263.
102. Aydingoz IE, Ferhanoglu B, Guney O. Does tissue iron status have a role in female alopecia? J Eur Acad Dermatol Venereol. 1999;13(1):65–67.
103. Boffa MJ, Wood P, Griffiths CE. Iron status of patients with alopecia areata. Br J Dermatol. 1995;132(4):662–664.
104. Bregy A, Trueb RM. No association between serum ferritin levels > 10 microg/l and hair loss activity in women. Dermatology. 2008;217(1):1–6.
105. Rushton DH, Dover R, Norris MJ. Is there really no clear association between low serum ferritin and chronic diffuse telogen hair loss? Br J Dermatol. 2003;148(6):1282–1284.
106. Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol. 2010;63(6):991–999.
107. Rushton DH, Bergfeld WF, Gilkes JJ, Van Neste D. Iron deficiency and hair loss–nothing new? J Am Acad Dermatol. 2011;65(1):203–204.
108. Olsen EARK. Untangling the hairy issue of iron deficiency: making progress. J Am Acad Dermatol. 2011;65(1):204–206. [Google Scholar]
109. Gowda D, Premalatha V, Imtiyaz DB. Prevalence of nutritional deficiencies in hair loss among Indian participants: results of a Cross-sectional Study. Int J Trichol. 2017;9(3):101–104. [PMC free article]
110. Deo K, Sharma YK, Wadhokar M, Tyagi N. Clinicoepidemiological Observational Study of acquired alopecias in females correlating with anemia and thyroid function. Dermatol Res Pract. 2016;2016:6279108. [PMC free article]
111. Dastgheib L, Mostafavi-Pour Z, Abdorazagh AA, et al. Comparison of zn, cu, and fe content in hair and serum in alopecia areata patients with normal group. Dermatol Res Pract. 2014;2014:784863. [PMC free article]
112. Esfandiarpour I, Farajzadeh S, Abbaszadeh M. Evaluation of serum iron and ferritin levels in alopecia areata. Dermatol Online J. 2008;14(3):21.
113. Mussalo-Rauhamaa H, Lakomaa EL, Kianto U, Lehto J. Element concentrations in serum, erythrocytes, hair and urine of alopecia patients. Acta Derm Venereol. 1986;66(2):103–109.
114. Bhat RM, Sharma R, Pinto AC, Dandekeri S, Martis J. Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichol. 2013;5(1):17–21. [PMC free article]
115. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088–1092. [PMC free article]
116. Ohyama M, Terunuma A, Tock CL, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest. 2006;116(1):249–260. [PMC free article]
117. Vinton NE, Dahlstrom KA, Strobel CT, Ament ME. Macrocytosis and pseudoalbinism: manifestations of selenium deficiency. J Pediatr. 1987;111(5):711–717.
118. Masumoto K, Nagata K, Higashi M, et al. Clinical features of selenium deficiency in infants receiving long-term nutritional support. Nutrition. 2007;23(11–12):782–787.
119. Petru E, Petru C, Benedicic C. Re: “Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy” Gynecol Oncol. 2005;96(2):559.
120. Fan AM, Kizer KW. Selenium. Nutritional, toxicologic, and clinical aspects. West J Med. 1990;153(2):160–167. [PMC free article]
121. MacFarquhar JK, Broussard DL, Melstrom P, et al. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med. 2010;170(3):256–261. [PMC free article]
122. Goskowicz M, Eichenfield LF. Cutaneous findings of nutritional deficiencies in children. Curr Opin Pediatr. 1993;5(4):441–445.
123. Alhaj E, Alhaj N, Alhaj NE. Diffuse alopecia in a child due to dietary zinc deficiency. Skinmed. 2007;6(4):199–200.
124. Kil MS, Kim CW, Kim SS. Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol. 2013;25(4):405–409. [PMC free article]
125. Yavuz IH, Yavuz GO, Bilgili SG, Demir H, Demir C. Assessment of heavy metal and trace element levels in patients with telogen effluvium. Indian J Dermatol. 2018;63(3):246–250. [PMC free article]
126. Abdel Fattah NS, Atef MM, Al-Qaradaghi SM. Evaluation of serum zinc level in patients with newly diagnosed and resistant alopecia areata. Int J Dermatol. 2016;55(1):24–29.
127. Ead RD. Oral zinc sulphate in alopacia areata-a double blind trial. Br J Dermatol. 1981;104(4):483–484.
128. Park H, Kim CW, Kim SS, Park CW. The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol. 2009;21(2):142–146. [PMC free article]
129. Passi S, Morrone A, De Luca C, Picardo M, Ippolito F. Blood levels of vitamin E, polyunsaturated fatty acids of phospholipids, lipoperoxides and glutathione peroxidase in patients affected with seborrheic dermatitis. J Dermatol Sci. 1991;2(3):171–178.
130. Wirth H, Gloor M, Swoboda U. Oral zinc therapy and sebaceous gland secretion (author’s transl) Z Hautkr. 1981;56(7):447–451.
131. Filoni A, Vestita M, Congedo M, Giudice G, Tafuri S, Bonamonte D. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: An observational case-control study. Medicine (Baltimore). 2018;97(25):e11185. [PMC free article]
132. Finner AM. Nutrition and hair: deficiencies and supplements. Dermatol Clin. 2013;31(1):167–172.
133. Goette DK, Odom RB. Alopecia in crash dieters. JAMA. 1976;235(24):2622–2623.
134. Krusinski PA. Letter: telogen effluvium secondary to weight loss and therapy with chorionic gonadotropin. Arch Dermatol. 1976;112(4):556.
135. Kaufman JP. Letter: telogen effluvium secondary to starvation diet. Arch Dermatol. 1976;112(5):731.
136. Boisvert A. Liquid protein diets and telogen effluvium: a case report. Ann Pharmacother. 1978;12(8):490–491. [Google Scholar]
137. Colombo VE, Gerber F, Bronhofer M, Floersheim GL. Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy. J Am Acad Dermatol. 1990;23(6 Pt 1):1127–1132.